Literature DB >> 11115713

Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice.

D G Alber1, R A Killington, A Stokes.   

Abstract

Glycoproteins C and D (gC and gD) derived from equine herpesvirus 1 (EHV-1)-infected cells were incorporated into individual solid matrix-antibody-antigen (SMAA) complexes and administered to BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Antibodies against each of the glycoproteins were produced that neutralised virus infectivity and mediated the lysis of EHV-1-infected target cells in the presence of complement. Immunoglobulin (Ig)G2b was the predominant antibody isotype produced in BALB/c mice against gC, while equal amounts of IgG2a/2b were found in the serum of C3H mice (indicative of a T-helper(1) response). Glycoprotein D immunisation elicited predominantly an IgG1 response in BALB/c mice (indicative of a T-helper(2) response) and an IgG2a/2b response in C3H mice. EHV-1-specific local and systemic T-cell proliferative responses were detected in vitro following administration of SMAA complexes. Suppression of the local T-cell response was seen following virus challenge of mice immunised with SMAA gC. SMAA gD provided some protection against intranasal EHV-1 challenge. These data show that the SMAA system is an effective way of presenting subviral components to the immune system and further emphasises the importance of including glycoprotein D as a component of a subunit EHV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115713     DOI: 10.1016/s0264-410x(00)00222-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Authors:  Maria Luisa Visciano; Michael Tuen; Miroslaw K Gorny; Catarina E Hioe
Journal:  Virology       Date:  2007-12-04       Impact factor: 3.616

3.  Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.

Authors:  Rajnish Kumar; Michael Tuen; Hualin Li; Doris B Tse; Catarina E Hioe
Journal:  Vaccine       Date:  2011-09-23       Impact factor: 3.641

4.  Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Authors:  Rajnish Kumar; Michael Tuen; Jianping Liu; Arthur Nàdas; Ruimin Pan; Xiangpeng Kong; Catarina E Hioe
Journal:  Vaccine       Date:  2013-09-16       Impact factor: 3.641

5.  Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex Vaccine.

Authors:  Rajnish Kumar; Maria Luisa Visciano; Hualin Li; Catarina Hioe
Journal:  J AIDS Clin Res       Date:  2012-03-09

6.  Characterization of the Streptococcus mutans P1 epitope recognized by immunomodulatory monoclonal antibody 6-11A.

Authors:  Nikki R Rhodin; Jenny M Cutalo; Kenneth B Tomer; William P McArthur; L Jeannine Brady
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

Authors:  Catarina E Hioe; Maria Luisa Visciano; Rajnish Kumar; Jianping Liu; Ethan A Mack; Rachel E Simon; David N Levy; Michael Tuen
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 8.  Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases.

Authors:  Alex F Tang; Gospel Enyindah-Asonye; Catarina E Hioe
Journal:  Vaccines (Basel)       Date:  2021-02-02

9.  A Plant-Derived Antigen-Antibody Complex Induces Anti-Cancer Immune Responses by Forming a Large Quaternary Structure.

Authors:  Deuk-Su Kim; Yang Joo Kang; Kyung Jin Lee; Lu Qiao; Kinarm Ko; Dae Heon Kim; Soon Chul Myeung; Kisung Ko
Journal:  Int J Mol Sci       Date:  2020-08-05       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.